Performance booster supplement DMAA draws national media attention
DALLAS — The Department of Defense’s investigation of a sports supplement ingredient — associated with the death of two soldiers — has been making headlines in the past week as the U.S. Military’s independent paper Stars & Stripes ran an update of the news on Jan. 29 and the New York Times picked up on the story Feb. 2.
The Army and Air Force Exchange Service in December pulled 18 supplements containing dimethylamylamine, or DMAA, that were sold on Army and Air Force bases through GNC because of a potential link to the deaths of two soldiers, according to a Stars & Stripes story published Dec. 5. The issue appears to be similar to that of ephedra, a dietary ingredient banned by the Food and Drug Administration in 2004. Ephedra generated national headlines as the deaths of two professional athletes — Korey Stringer of the National Football League’s Minnesota Vikings and Steve Bechler of Major League Baseball’s Baltimore Orioles — were linked to the use of ephedra supplementation. Like ephedra, DMAA is used as a performance booster.
A subsequent Stars & Stripes report confirmed that the U.S. Army soon thereafter began investigating the link between DMAA supplementation and the deaths of the two soldiers, both of whom suffered heart attacks, following toxicology reports that were positive for DMAA. "The Army launched an ongoing safety review after recording a number of other serious health effects among known and potential users of products containing DMAA including ‘kidney and liver failure, seizures, loss of consciousness, heat injury and muscle breakdown during exertion, and rapid heartbeat,’" the military daily reported Dec. 15, citing a written response from Army spokeswoman Maria Tolleson.
“Compared to the handful of adverse event reports recently cited by the Army, GNC has sold 440 million doses of product containing DMAA since 2007 and has not received a single serious adverse event report,” GNC spokesman Greg Miller told Stars & Stripes, according to the report.
The manufacturer identified in the reports is USPLabs, which is selling the DMAA supplements under such brand names as Jack3d and OxyElite Pro.
For the Dec. 29 Stars & Stripes story, click here.
For the Feb. 2 the New York Times story, click here.
For the original Dec. 5 Stars & Stripes story, click here.
Prilosec OTC, John Madden recognize New Orleans Saints offensive line
CINCINNATI — The National Football League’s New Orleans Saints offensive line has been selected as the winner of the 2011 Madden Protectors Award, presented by Procter & Gamble’s Prilosec OTC and Hall of Fame coach John Madden, in honor of the NFL’s best offensive line, during a press event in Indianapolis.
Accepting the trophy on behalf of the New Orleans Saints were offensive linemen Jahri Evans, Carl Nicks, Zach Strief, Brian De La Puente and Jermon Bushrod.
“The offensive line doesn’t always catch the fans’ attention, so Prilosec OTC and I created this award to recognize the guys who provide the critical run blocking and pass protection,” Madden said. “All season long, these five guys proved they had the mental and physical toughness that enabled the Saints offense to put up big numbers on the ground and in the air.”
Study: In Type 2 diabetics not on insulin, self-monitoring has no impact on disease
CHICHESTER, England — Self-monitoring blood glucose levels in Type 2 diabetics not on an insulin regimen may contribute little to managing the disease, according to an analysis published online last month by The Cochran Library.
"Based on a best-evidence synthesis, there is no evidence that [self-monitoring blood glucose] affects patient satisfaction, general well-being or general health-related quality of life," concluded lead author Uriëll Malanda, of the VU University Medical Center, Department of General Practice, EMGO Institute for Health and Care Research in Amsterdam, Netherlands. "More research is needed to explore the psychological impact of [self-monitoring blood glucose] and its impact on [diabetics’] specific quality of life and well-being, as well as the impact of [self-monitoring blood glucose] on hypoglycemia and diabetic complications."
According to the analysis, it was assumed that patients with Type 2 diabetes who are not using insulin would be using the glucose values to adjust their diet and lifestyle. "Pooled results of studies including patients diagnosed with Type 2 diabetes for at least one year show that self-monitoring of blood glucose has a minimal effect in improving glucose control at six months, which disappears after 12 months follow-up," Malanda wrote. "The clinical benefit resulting from this effect is limited."